Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
NCT ID: NCT00985036
Last Updated: 2012-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2009-09-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
2. Is the VEGF level an indicator of the response to treatment?
3. Does the VEGF level correlate with tumor histology and behavior?
4. Is there a relationship between VEGF level and outcome?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.
NCT03526822
Biomarkers for Prognosis of Glioblastoma (GBM)
NCT01493219
Cerebrospinal Fluid Biomarkers for Brain Tumors
NCT04692324
Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
NCT06709833
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
NCT00005082
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glioma
patients who are diagnosed with and are being treated for glioma
Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
meningioma
patients who are diagnosed with and are being treated for meningioma
Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test
an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Upper Michigan Brain Tumor Center
OTHER
Marquette General Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard A. Rovin, MD FACS
Neurosurgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard A Rovin, MD, FACS
Role: PRINCIPAL_INVESTIGATOR
Upper Michigan Brain Tumor Center
Robert J Winn, PhD
Role: PRINCIPAL_INVESTIGATOR
Northern Michigan University
Suresh Nukala, MD
Role: PRINCIPAL_INVESTIGATOR
Marquette General Health Systems
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Marquette General Hospital
Marquette, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MGH-VEGF-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.